Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway
about
Alcoholism: A Systems Approach From Molecular Physiology to Addictive BehaviorPsychotropic analgesic nitrous oxide for alcoholic withdrawal statesReview. The neurobiology of pathological gambling and drug addiction: an overview and new findingsBuprenorphine: a unique drug with complex pharmacologyKappa opioids as potential treatments for stimulant dependenceLong-lasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: time course of mu-opioid receptor mRNA and FosB/DeltaFosB immunoreactivityDynorphin, stress, and depressionNeurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodentsKappa-opioid ligands in the study and treatment of mood disordersKappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responsesSocial defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid systemStructure-based discovery of opioid analgesics with reduced side effects.Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on AddictionEffects of anabolic-androgens on brain reward function15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuseThe dopamine system and alcohol dependenceκ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addictionRole of kappa-opioid receptors in stress and anxiety-related behavior.Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in HumansDynorphin Controls the Gain of an Amygdalar Anxiety CircuitEthanol action on dopaminergic neurons in the ventral tegmental area: interaction with intrinsic ion channels and neurotransmitter inputs.Mechanistic insights into nicotine withdrawal.Neurobiology of aversive states.A Trigger for Opioid Misuse: Chronic Pain and Stress Dysregulate the Mesolimbic Pathway and Kappa Opioid SystemCyclazocine revisitedRole of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuseInfluence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholismOrphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in ratsReduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addictionDisruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawalNaloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphineAnhedonia to music and mu-opioids: Evidence from the administration of naltrexoneSalvinorin A analogs as probes in opioid pharmacology.Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humansIncreased dopamine receptor activity in the nucleus accumbens shell ameliorates anxiety during drug withdrawal.Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependenceNeuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin AAn anatomical basis for opponent process mechanisms of opiate withdrawalThe effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.
P2860
Q22241964-F5E5B43A-8015-4B58-8160-691F3C06FB1DQ24245367-D4F2E4F1-4EC2-4CBC-A68F-ECEACEABBBDFQ24641954-B1C5493C-A78F-44AF-89E0-E8C5AC5FE700Q24642980-CB3B68C1-D9ED-41FA-8502-6066E583FF7FQ24647849-41DE271D-CF6C-4C64-9FFC-28935AB3CBAFQ24648008-A5678B8F-A4D3-4FB0-BD2E-5F5DD84D6E45Q24650168-3C48143C-0830-438E-B24B-1054F613C5F8Q24656267-C7DF7C9F-C9B5-4E5F-9FDF-7721F9E00949Q24657982-93AF72FB-6FD3-4EE8-864E-726BE50AD04EQ24683322-9F9E7081-FFA7-420B-8FB4-45D4DC757AE5Q24685275-22BF705D-B581-4CD8-BEE4-F0B9E26FEDD8Q26331003-0DD9969D-E012-4DF8-9BCD-7B40B64D1FFDQ26770785-4968ECB3-02B7-42E0-B232-13BB40C92F4DQ26785394-AC1AC46C-12C6-4B90-8D08-A3B24D6F9EF2Q26824667-95248143-22A0-47D5-B2C6-AAAA77CB8275Q26828888-C9494A60-4292-4372-923C-C02CF9DC31FDQ26864309-A3836110-7098-4825-9845-B616F3850ABFQ26991739-6446559A-80F7-4592-A535-6E9D8004A056Q27300685-2FBB6047-6A48-4D9A-B56B-F440A562212CQ27319741-B402BD56-37BB-4AEB-BA70-1E3B84CC8B65Q27687624-ACD9D3C6-5254-401F-8045-6A1FAA624EDFQ27687645-B7DF698C-69F4-4C15-AE35-8EC73F253BB6Q27687846-98B9A219-004D-4C0D-8647-179378AAF54DQ28074686-EE1922E7-9738-4E3E-BBB8-BFD21EFD02D7Q28298711-A21297FF-5A3A-4789-B76D-2DC0D5670C3AQ28306056-0ED55178-5C99-4062-B7C5-E3AAC61B4FB8Q28361170-EB06DB2F-E044-40EC-BDC6-84034B773316Q28362126-2A81F308-9A41-43A2-9C28-8C9CABBB4E75Q28363073-DF9A5539-F481-4250-9A5A-740BD3E05F96Q28379331-C3A0DC2D-3AAC-4115-8C6E-F5BBFA57800BQ28573276-8ACE79A8-807A-4480-8D2B-D5D2E5106080Q30363430-B899D1D6-140A-42CE-9261-06D211D754EFQ30439719-59DCBB0D-A48B-4691-958B-DD3FB06BCBEAQ30440516-AE89E3CF-50AE-48B5-9AE9-EC3275D09145Q30447153-1617701F-7F42-4DF2-8CA4-25697E3F9AD2Q30448787-B0C6285F-3581-4445-A44F-C9E1FF6699D5Q30453617-DD5E4021-D61F-41D7-A7DD-A6842446957CQ30467220-677597C6-EAEB-4F18-B97E-D232785EB132Q30472851-D9EA4DE3-D87F-41E5-BEE3-BF237457719FQ30479463-B37136CC-3C45-40C6-B20C-DAB0AA3202F4
P2860
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Opposing tonically active endo ...... esolimbic dopaminergic pathway
@en
type
label
Opposing tonically active endo ...... esolimbic dopaminergic pathway
@en
prefLabel
Opposing tonically active endo ...... esolimbic dopaminergic pathway
@en
P2093
P2860
P356
P1476
Opposing tonically active endo ...... esolimbic dopaminergic pathway
@en
P2093
R Spanagel
T S Shippenberg
P2860
P304
P356
10.1073/PNAS.89.6.2046
P407
P577
1992-03-01T00:00:00Z